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Role of Interferon in Cancer 
Metabolism
Vaishali Chandel and Dhruv Kumar
Abstract
Interferons (IFNs), a pleotropic cytokine that has long been regarded as an 
important effector molecule, are increasingly recognized due to their role in cancer 
and in antitumor immune response regulation. Interferons broadly alter cellular 
functions in response to viral and other infections. Dysregulation of interferon has 
been implicated in cancer, autoimmune disorders, and pathogenesis of chronic viral 
infections. However, the association between interferons and cancer cell metabo-
lism is poorly understood. Emerging evidence suggests the importance of lipid, 
energy, and amino acid metabolic pathway in regulating interferon response against 
cancer. Additionally, viruses exploit and modulate the host cell and induce the 
major metabolic reprogramming causing cancer. In response, interferons upregu-
late the transcription of large number of interferon stimulating gene (ISG) whose 
products play a major role in the innate and adaptive immune response against viral 
infection. Immense research is being done on understanding the role of IFNs in 
cancer metabolism. Therefore, systematic evaluation of these associations between 
interferons and cancer metabolism may have important implications for the devel-
opment of anticancer therapeutics targeting IFN, minimizing toxicity, and limiting 
off-target effects.
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1. Introduction
The interferons (IFNs) are a family of pleotropic cytokines, which play an 
important role in anticancer immune response. IFNs broadly modulate cellular 
functions in response to viral and other infections. These modulations include 
changes in membrane composition, proliferation, metabolism, protein synthesis, 
and the nutritional microenvironment [1]. Interferons (IFN) are classified as three 
major types distinguished by their nature, sequence identity, and distribution of 
cognate receptors [1]. The type I human IFN encodes a family of 17 distinct proteins 
(IFNα 13 subtypes, IFNβ, IFNε, IFNκ, and IFNω) consisting of IFNα/β receptor 
1 (IFNAR1) and IFNα/β receptor 2 (IFNAR2) subunits that bind to their cognate 
receptor. The type 1 IFN is located on chromosome 9p. Engagement of receptor 
activates the receptor-associated protein tyrosine kinases Janus kinase 1 (JAK1) 
and tyrosine kinase 2 (TYK2), phosphorylating and activating signal transducer 
and activator of transcription 1 (STAT1) and STAT2 transcription factors [2]. IFNγ 
is the only single type II IFN, which binds to IFNγ receptor 1 (IFNGR1) and IFNγ 
receptor 2 IFNGR2 subunits. The type III IFNs consist of IFNλ1, IFNλ2, IFNλ3, 
and IFNλ4, which bind the IFNλ receptor 1 (IFNLR1) [3] (Figure 1). Pattern 
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recognition receptor (PRR) pathways activate the expression of type I and type III 
IFNs. However, cytokines expressed by natural killer (NK) cells and T cells, includ-
ing IL 12 and IL 18, or mitogens induce type II IFN [4, 5]. Additionally, mammalian 
target of rapamycin (mTOR) also activates the expression of IFNs. Integration of 
mTOR complex 1 (mTORC1) with the major class of energy and nutrient sources 
[glucose, amino acids, adenosine triphosphate (ATP), and lipids] leads to the cel-
lular activation and translation [6]. mTORC1 activation is important to induce and 
activate interferon regulatory transcription factor (IRF) such as IRF5 and IRF7, to 
initiate and maximize the production of type I IFN [7]. The transcription of major-
ity of interferon stimulated genes (ISGs) is mediated by type I IFNs and IFNγ [8]. 
Three major families of ISGs play a major role in antiviral host immune response; 
RNA-activated protein kinase (PRK), Mx protein (Myxovirus resistance 1) and 
ribonuclease L (RNase L) [9]. They are responsible for inhibiting viral replica-
tion. PKR is induced by IFN and is a RNA-dependent kinase that phosphorylates 
eIF2α, the translation initiation factor 2α mediating inhibition of viral and cellular 
translation. Binding of dsRNA activates OAS and stimulates the activity of RNase 
L causing protein expression inhibition by cellular and viral ssRNA cleavage [10]. 
In addition, Mx proteins are GTPases, which trap and inhibit viral replication by 
sensing nucleocapsid-like viral structures [11]. The production of IFNs is important 
Figure 1. 
Interferon signaling and role in cancer. Type I IFN encodes IFNα/β consisting of IFNα/β receptor 1 and 2 
subunits that bind to their cognate receptor. Engagement of receptor activates JAK1 and TYK2, phosphorylating 
and activating STAT1 and STAT2 transcription factors. IFNγ binds to IFNγ receptor 1 and 2 subunits. The type 
III IFNs consist of IFNλ1, which bind the IFNλ receptor 1 and 4. Activation of the three types of interferons 
mediates downstream signaling pathway in cancer and leads to effector responses such as anti-proliferative, 
antiviral apoptosis, metabolic regulation, immunoregulation, migration, cellular growth and differentiation, 
growth inhibitory effects, and cell cycle progression. JAK1: Janus kinase 1; TY2: tyrosine kinase 2; STAT: signal 
transducer and activator of transcription.
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since they regulate tumorigenesis and mediate metabolic reprogramming by direct 
or indirect means [1, 12]. IFN plays a major role in cancer metabolism. Cellular 
metabolism is a complex and fundamental biological process involving catabolism 
to fuel cellular reactions by the breakdown of macromolecules to generate energy 
in the form of adenosine triphosphate (ATP) and anabolism that delivers nutrients 
such as amino acids, carbohydrates, and fatty acids for the synthesis of macromol-
ecules [13]. As compared to the normal cells, the metabolic activities in cancer cells 
are altered, and these alterations facilitate and support the malignant properties of 
cancer cells. Therefore, metabolic reprogramming is one of the major hallmarks of 
cancer [14]. In order to meet biosynthetic and bioenergetic demands to facilitate 
rapid proliferation, cancer cells perform increased glycolysis even under anaerobic 
conditions (Warburg phenomenon) [15]. Thus, the conversion of glucose to lactic 
acid by glucose metabolism fulfills energy demands in cancer cells, as opposed to 
mitochondrial oxidative phosphorylation in normal cells [16]. Additionally, reliance 
on glycolysis by cancer cells is a useful adaptation in order to sustain in a hypoxic 
microenvironment. This glycolytic switch is mediated by various mechanisms [17]. 
For example, the best described canonical pathway mediating the regulation of 
tumor cell metabolism is the PI3K-Akt pathway [18]. PI3K-Akt pathway promotes 
the activity of glucose transporter (GLUT) and stimulates the glycolytic process 
and production of lactate through activating several glycolytic enzymes such as 
hexokinase (HK) and phosphofructokinase (PFK). Mechanistically, PI3K-AKT 
signaling activates mammalian target of rapamycin (mTOR), which activates the 
transcription factor in turn, hypoxia-inducible factor-1 (HIF-1). HIF-1 cooperation 
with other transcription factors such as p53, c-Myc, and Oct1 activates transcription 
of multiple genes involved in glycolytic metabolism, such as HK [19], GLUT-1 and 
GLUT-3 [20, 21], lactate dehydrogenase (LDH) [22], and phosphoglycerate kinase 
[23], as well as for pH regulation, such as carbonic anhydrase IX (CAIX) [24] and 
Na+/H+ exchanger 1 (NHE1) [25], and suppressors of TCA cycle, such as pyru-
vate dehydrogenase kinase (PDK) [26]. However, metabolic alteration in cancer 
cell is not only defined to glucose metabolism, but it is directly interconnected 
with various other metabolic pathways such as amino acid metabolism through 
the intermediate 3-phosphoglycerate, pentose phosphate pathway (PPP) by the 
glucose-6-phosphate intermediate, and metabolism of fatty acids (FA) by pyruvate 
into Krebs cycle [27].
Therefore, it is important to understand the role of interferons in cancer cell 
metabolism for the development of novel interventions to treat cancer.
2. Interferons and cancer metabolism
2.1 Type I IFN signaling and cancer metabolism
The correlation between the type I IFN and cancer metabolism in cancer is 
shown in several studies [1, 7, 12, 29, 51]. However, the mechanism underlying this 
altered metabolism is poorly understood and not widely studied because of the 
complexity in regulation by various cellular extrinsic and intrinsic signals [28]. 
Signaling pathway, including JAK/STAT, ERK/MAP, p38, and PI3/AKT, regulate the 
metabolic process [29]. Additionally, it has been shown that IRF also plays a major 
role in regulating metabolism in cancer [30]. The JAK/STAT signaling pathway 
plays an important role in regulating development, immune function, and apopto-
sis [34]. It regulates the expression of early response genes [31]. STAT1 and STAT3 
alter the gene expression in glucose metabolism, gluconeogenesis, Krebs cycle, and 
mitochondrial oxidative phosphorylation (OXPHOS). Apart from this metabolic 
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pathway, STAT 1 and STAT3 play a key role in modulating lipid metabolism in 
cancer [32–34]. Also, they have been shown to alter the cellular respiration process 
and mitochondrial function. The function of mitochondria is decreased due to 
PPARG coactivator-1 α (PGC-1 α) repression, a master regulator in mitochondrial 
biogenesis [35]. Alternatively, STAT3 localizes in mitochondria and interacts with 
complex I and II of the electron transport chain (ETC), thereby increasing the 
oxidation process [36]. Most importantly, while these modifications in metabolic 
pathways are needed to mount functional immune responses, changes associated 
with STAT activation may lead to the pathogenic processes during activation of 
IFN. Specifically, signaling mediated by STAT1 has been shown to mediate tumori-
genesis and resistance to chemotherapy and ionizing radiation by upregulating the 
expression of genes involved in glucose metabolism, Krebs cycle, and OXPHOS 
[37]. Alternatively, alterations driven by STAT3 in mitochondrial metabolism lead 
to drug resistance in cancer patients by controlling the mitochondrial transition 
pore opening [38]. However, further study is needed to understand how these 
STAT mediated mechanisms facilitate to functional and nonfunctional type I IFN 
responses. Apart from the STAT signaling pathway, AKT/mTOR signaling has been 
shown to play an important role in type I IFN effector function regulation. The two 
complexes of mTOR (mTORC1 and mTORC2) [39, 40] have differential effects on 
type I IFN responses. mTORC1 plays a key role in ISGs translation [41], whereas 
mTORC2 performs transcription of IFN-dependent gene via interferon-stimulated 
response elements [42]. Additionally, mTOR in response to hormonal and environ-
mental signals coordinates metabolism centrally [43]. Also, it has been associated 
with lipogenesis, adipogenesis, ribosomal biogenesis, and pyrimidine synthesis 
[44–47]. Previous studies have identified the correlation between mTOR signal-
ing, OXPHOS, fatty acid oxidation (FAO), and glycolysis with type I interferons 
[48]. A major important regulator of interferon responses is IRFs, which centrally 
regulate the development of immune cell and effector function [30, 49–51]. The 
best described IRFs, IRF4, regulate the expression of the major molecules, which are 
important for aerobic glycolysis [49] and for suppressing the expression of lipogenic 
gene involved in lipogenesis and lipolysis activation [84]. In a similar manner, IRF5 
upregulates the glycolytic process via activation of AKT and glycolytic gene induc-
tion in inflammatory macrophages [51]. Many studies have reported abnormalities 
in expression of IRF and their role in metabolic diseases such as cancer with poor 
prognosis, insulin resistance, atherosclerosis, and hepatic steatosis [52–54].
2.2 Type I IFN and altered bioenergetics
Metabolic reprogramming in cancer cells is closely linked to effector function 
and cellular activation [55]. Bioenergetic pathways include glucose metabolism, tri-
carboxylic acid cycle (TCA), FAO, OXPHOS, electron transport chain (ETC), and 
pentose phosphate pathway (PPP) [55]. Since metabolic reprogramming is needed 
to meet the biosynthetic and bioenergetic demands of the cells, recent studies sug-
gest that metabolites (succinate and citrate) and enzyme pyruvate kinase M2 may 
play a key role and act as transcription factor and signaling molecule to mediate the 
immune function and inflammatory processes [27, 56, 57]. An important charac-
teristic of type I IFN in cancer metabolism is upregulated glucose metabolism [58]. 
The metabolic shift is important to quickly generate ATP to meet energy demands 
of the cell. In fibroblasts, PI3/AKT signaling is important for type I IFN-associated 
shift and leads to increased uptake of glucose in the cell [59]. Alternatively, 
STAT1 mediates aerobic glycolysis in human squamous cell carcinoma [60]. Also, 
upregulated expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
3 (PFKFB3) has been shown in variety of tumors [61] (Table 1). Furthermore, the 
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metabolic shift from OXPHOS to glycolysis contributes to Warburg phenomenon, 
tumor metastasis, and growth [62]. In cancer cells, decreased rate of mitochondrial 
OXPHOS is accompanied with the glycolytic shift in immune cells [63]. Consistent 
with these findings, mouse L929 cell triggered with type I IFN showed signs of 
reduced OXPHOS and production of ATP [64]. Also, CD4+ T cells isolated from 
multiple sclerosis patients treated with IFN-β underwent OXPHOS impairment 
in a dose-dependent manner as compared to healthy individuals [65]. A single 
nucleotide polymorphism (SNP) in PGC-1α, a gene involved in the mitochondrial 
biogenesis, was shown to be associated with reduced intracellular ATP production 
levels and altered therapeutic response to IFN-β in patients [65]. However, other 
studies suggest that bioenergetic reprogramming in cancer driven by IFN may be 
context and cell type dependent [66]. Mouse plasmacytoid DCs (pDCs) stimulated 
by IFN-α are linked with upregulated glycolytic genes in turn increased glycolysis, 
OXPHOS, and FAO to meet the energy demand of the cells [67]. mTOR activation 
mediates upregulation of OXPHOS and FAO and is important in mounting an 
immune response. In T cell, stimulation of CD8+ memory T cells by IFN-α is associ-
ated with upregulated OXPHOS, whereas effector T cell stimulation has not been 
shown to alter the activity of OXPHOS [68]. Additionally, in the reverse Warburg 
phenomenon, cancer cells induce aerobic glycolysis in cancer-associated fibroblasts 
(CAFs), present in the tumor stroma. CAFs generate pyruvate, lactate, and ketone 
bodies that enter the TCA cycle in cancer cells for mitochondrial OXPHOS. In fact, 
these tumor-associated stromal cells, for example, tumor-associated macrophages 
(TAMs), already vary from their original cells and have epigenetic and genetic 
changes, which result in altered metabolic profiles. Therefore, cancer cells influence 
Gene Role in metabolism Cancer type Reference
PFKFB3 Regulator of glycolysis. Associated with many 
aspects of cancer, including metabolism, 
carcinogenesis, cancer cell proliferation, vessel 
aggressiveness, drug resistance, and tumor 
microenvironment
Liver, breast, 
head, and neck
[61]
SC4MOL Protection against virus attack and important 
contributor in sterol metabolism
Breast, nonsmall 
cell lung cancer
[74]
SCAP IFN-driven regulation of lipid metabolism Brain cancer [71, 72]
SREBP1/2 IFN-driven regulation of lipid metabolism Colon, lung, 
pancreatic
[88]
CH25H Regulate cellular functions and influence various 
physiological processes such as cholesterol 
metabolism, membrane fluidity regulation, and 
intracellular signaling pathways in cancer
Breast cancer [89]
CYP27A1 Affects estrogen receptor function by the 
antagonism of estrogen action and also by the direct 
modulation of the receptor function modulating 
metabolism
Breast cancer [76]
IDO1 Prevents viral proliferation and regulates lipid 
metabolism and inflammation
Breast, lung, 
pancreatic, 
leukemia
[90]
NOS2 Cytostatic and cytotoxic effects against tumor cells Glioblastoma, 
melanoma, 
breast
[91]
Table 1. 
Type I IFN immunometabolic gene response in the progression of various cancers.
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each other not only in terms of growth factor or cytokines, such as IFN, but also 
on dependency on metabolic pathways. TAMs, for example, derive their ATP from 
OXPHOS rather than aerobic glycolysis.
2.3 IFN response and lipid metabolism
A wide variety of studies have recognized the role of type I IFNs in modulat-
ing lipid metabolism in cancer [7]. Lipids are the major constituent in plasma 
membrane and various other cellular compartments such as the endoplasmic 
reticulum, nuclear membrane, Golgi apparatus, lysosomes, and endosomes [7]. 
Alongside, lipids function as signaling molecules to regulate the majority of cellular 
processes, including inflammatory, metabolic, and innate immune responses [69]. 
A number of viruses causing cancer, such as Epstein-Barr Virus (EBV), Hepatitis 
B Virus (HBV), Hepatitis C Virus (HCV), Human Herpesvirus 8 (HHV8), Human 
Papillomavirus (HPV), Human T-cell Lymphotropic Virus 1 (HTLV), and Merkel 
Cell Polyomavirus hijack cholesterol and fatty acid (FA) biosynthesis of host to 
support replication and survival of virus [70]. To counteract this process, de novo 
cholesterol and lipid synthesis is decreased, and cholesterol and FA import is medi-
ated by type I IFNs. After 30 min of exposure to IFN, STAT2-driven reprogramming 
occurs and is independent of ISG expression [71]. Decreased de novo cholesterol 
and lipid synthesis is a complex mechanism and needs further research to be done 
upon. Several studies have reported the role of sterol regulatory element-binding 
protein 2 (SREBP2)/SREBP cleavage-activating protein (SCAP) pathway in IFN-
driven regulation of lipid metabolism [71, 72] (Table 1). SPREBP1 and SREBP2 are 
recruited by SCAP, a chaperone protein to the nucleus. In the nucleus, SPREBP1 and 
SREBP2 transcription factors regulate cholesterol and lipid metabolism, respec-
tively. Knock out of SREBP2 or SCAP expression in macrophages leads to mice 
resistant to viral attack supporting the role of IFN response and an interrelation-
ship between lipid metabolism and type I IFN [71, 72]. Additionally, type I IFNs 
upregulate microRNAs that control cholesterol biosynthesis. Upregulated expres-
sion of miR-342-5p in BMM is shown to be associated with IFN-β stimulation. 
miR-342-5p targets SREBP2, DHCR7, IDI1, and SC4MOL cholesterol biosynthetic 
genes [73] (Table 1). SC4MOL gene catalyzes demethylation of C4-methylsterols 
and meiosis-activating sterols (MASs) and encodes methyl sterol oxidase (Table 1). 
Accumulation of C4-methylsterols leads to increased proliferation of cancer cells 
[74]. Oxysterol, a cholesterol derivative participating in cholesterol metabolic 
regulation, signaling pathways such as Hedgehog, MAPK, and Wnt, and enzymatic 
activity playing a major role in cancer metabolism, is upregulated by type I IFNs 
[75]. Of the most important, 25-hydroxycholesterol (25-HC) and 27-HC (CYP27A1) 
play a key role in sterol biosynthesis regulation, minimizing accumulation of 
cholesterol and inhibition of viral spread and replication [76]. Cholesterol-25-
hydroxylase (CH25H) encodes 25-HC, which is a soluble oxysterol [38]. Type I 
and II IFN production in response to Toll-like receptor (TLR) activation leads to 
the expression of CH25H in dendritic cells and macrophages. 25-HC does this by 
repressing the activation of SREBP2 or by increasing the expression of miR-185 
regulating hepatic homeostasis of lipid [7]. Alternatively, 27-HC has been demon-
strated to decrease the cholesterol accumulation in lysosomes and decrease inflam-
mation [7] (Table 1). However, oxysterol induced by IFN may also have a damaging 
role in cancer and other inflammatory diseases. 25-HC amplifies proinflammatory 
mediator production following infection [77]. 22-HC and 27-HC in cancer are 
detected in high levels in a majority of tumor cells [78, 79]. They mediate the activa-
tion of liver X receptors (LXRs) in tumor, upregulating the efflux of cholesterol 
while promoting an anti-inflammatory state [80]. Additionally, 22-HC and 27-HC 
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have been reported to enhance the estrogen receptor transcription in breast cancer 
model, supporting the evidence that it may lead to resistance to hormonal therapy 
[78] (Table 1).
2.4 IFN response and amino acid metabolism
Amino acids serve as a building block for protein synthesis, branched chain fatty 
acid synthesis, and energy metabolism [27]. Their utilization is associated with 
metabolic signaling pathway such as nucleotide synthesis and mTOR pathway in 
tumor cells during immune response. Amino acid metabolism is reprogrammed 
to meet the biosynthetic and bioenergetic requirements of the cells [27]. However, 
several other studies have shown the role of amino acid as an important signaling 
molecule to alter cellular survival and function [27]. For the purpose of the impor-
tance of interferons in cancer-associated metabolism, we will focus on arginine and 
tryptophan metabolism in regulating type I IFN responses.
In response to type I IFN, metabolism of amino acid is tightly regulated against 
virus causing cancer [81]. A major example of this regulation includes tryptophan 
metabolism. Tryptophan is one of the nine essential amino acids and is very 
important in playing a key role in various metabolic pathways. The catabolites of 
tryptophan play an important role in cancer immunosuppression. Indoleamine-2,3-
dioxygenase (IDO), catabolic enzyme converting tryptophan to kynurenine, is the 
essential rate limiting enzyme expressed in antigen-presenting cells or tumor cells. 
This metabolic pathway creates an immunosuppressive milieu in tumor-draining 
lymph nodes and in tumors by inducing apoptosis and T-cell anergy through 
tryptophan depletion and accumulation of immunosuppressive tryptophan catabo-
lites. Specifically, the synthesis of tryptophan derivatives in kynurenine accounts 
for more than 80% of tryptophan catabolism. The synthesis of kynurenine is done 
by the catalytic activity of tryptophan-2,3-dioxygenase (TDO2) and indoleamine-
2,3-dioxygenase (IDO1) (Figure 2). The expression of ISG (interferon-stimulated 
gene), IDO1, which is highly effective at controlling and resisting pathogens, is 
very high across different cell types, whereas TDO2 has a lower affinity for tryp-
tophan and is majorly expressed in hepatocytes [7]. Several studies have shown 
the development of an immunotolerant state associated with enhanced regula-
tory response of T cells and suppressed T cell activation and proliferation due to 
increased tryptophan catabolism [82, 83]. Additionally, metabolites of kynurenine 
including 3-hydroxyanthranilic acid and quinolinic acid have cytotoxic as well as 
inflammatory effects [84]. These studies suggest the role of tryptophan catabo-
lism in response to type I IFN in a protective or detrimental manner in cancer. 
Supporting their protective role, studies have demonstrated that induction of IDO 
can be important in autoimmune disease prevention and cancer [85]. Consistent 
with such findings, IDO protein is expressed in varieties of solid tumor and in 
human malignancies [86] (Table 1). These findings and observations highlight 
the importance of type I IFN in the development of anticancer therapeutics by 
modulating tryptophan catabolism pathway. In addition to the role of type I IFN in 
modulating tryptophan metabolism, arginine plays an important role in adaptive 
and innate immune response [86]. Arginine is catabolized by four different classes 
of enzyme in various cell types: arginase, arginine: glycine amidinotransferase 
(AGAT), nitric oxide synthase (NOS), and arginine decarboxylase (ADC) [87]. This 
catalytic process produces several metabolites, which are biologically important 
with various functions such as urea, citrulline, glutamate, creatinine, polyamines, 
and nitric oxide (NO). Arginine is metabolized by arginase and/or NOS pathway 
[12]. The specific role of arginase or iNOS leads to the functional polarization of 
these cells into anti-inflammatory M2 phenotypes or M1 inflammatory phenotypes 
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[12]. The expression of iNOS is increased by type I IFN and is linked to enhanced 
levels of NO, L-citrulline, and reactive nitrogen species. Furthermore, enhanced 
glycolysis in tumor cells, TAMs, and other stromal cells, such as CAFs, leads to lactic 
acid accumulation in the tumor microenvironment. Lactic acid polarizes TAMs to a 
tumor-promoting phenotype characterized by the expression of arginase1 (ARG1), 
VEGFA, and several M2 markers via the activation of HIF1α [12]. This metabolic 
reprogramming results in accumulation of bioactive metabolites and plays a major 
role in cytotoxic or cytostatic activities against tumor cells. This suggests that type 
I IFN signaling may play an important role in tumor immune escape, immunosup-
pression, and immunopathology [12].
3. IFN-γ and cancer metabolism
In cancer, metabolic reprogramming of macrophages has been widely studied, 
but its relevance in function of inflammatory cell is a current research interest. 
Considering the role of Warburg phenomenon (aerobic glycolysis) in M1 mac-
rophages, researchers have been dependent on 2-DG, a competitive inhibitor of 
glucose in the first reaction step. It was found that induction of 2-DG downregu-
lated both aerobic glycolysis and mitochondrial OXPHOS and had a significant 
effect in a dose-dependent manner on cell viability and ATP levels. Alternatively, 
they exploited galactose, which is metabolized to glucose-6-phosphate at a 
very slow rate, thereby significantly downregulating the glycolytic throughput. 
Additionally, it was observed that there was downregulation in extracellular 
acidification rate (ECAR) levels with little effect oxygen consumption rate (OCR), 
thereby facilitating more exclusive evaluation of the importance of glycolysis in M1 
macrophages. Certainly, even under those conditions, macrophages were differenti-
ated by IFN-γ into M1 type phenotype depending on the surface marker expression 
Figure 2. 
Tryptophan catabolism in response to type I IFN. The synthesis of kynurenine is done by the catalytic activity 
TDO2 and IDO1. Increased tryptophan catabolism suppresses T cell activation, and proliferation IDO is an 
important mediator in metabolism, autoimmune disease prevention, and cancer. TDO2, tryptophan-2,3-
dioxygenase (TDO2); IDO1, indoleamine-2,3-dioxygenase.
9Role of Interferon in Cancer Metabolism
DOI: http://dx.doi.org/10.5772/intechopen.92020
and cytokines such as IL-6 and TNF-α. However, levels of IL-1β and HIF-1α were 
profoundly downregulated by galactose, similar to the expression and production 
of NO. Consistent with these findings, it suggests that aerobic glycolysis in cancer 
is very particular and plays a significant role for two gene transcription pathways 
in IFN-γ-stimulated macrophages: HIF-1α and STAT-1. In a similar manner, IFN-γ 
activated JAK/STAT-1 pathway in cancer increased phosphorylation of STAT-1 in 
M1 macrophages, and this response was inhibited by using 2-DG as a competitive 
inhibitor. Also, TAMs showed an increased glycolysis, and glycolysis inhibition 
using a competitive inhibitor 2DG revoked the functional phenotype of cancer 
cells. Galactose showed a significant inhibitory effect on the phosphorylation of 
STAT-1, supporting the importance of aerobic glycolysis in JAK/STAT-1 pathway. In 
the absence of IFN-γ, glucose itself could not stimulate JAK/STAT-1 pathway. These 
findings highlight the importance of IFN-γ triggering signaling pathway in M1 
macrophages altering the metabolism in cancer [12].
4. Conclusions
The interrelationship between immune function and cellular metabolism is 
increasingly recognized. Apart from providing substrates to meet the biosynthetic 
and bioenergetic demand, metabolites from metabolic pathway and enzymes 
regulate transcription and translation, epigenetic processes, signaling pathways to 
control cellular function. Increasing evidence suggests the importance of interfer-
ons in modulating cell metabolism in cancer and contributing to effector functions. 
However, it is unclear if these processes can be harnessed to elicit specific immune 
functions and/or prevent the development of pathological side effects. In order to 
target metabolic processes with some level of specificity, we require an in-depth 
understanding of how these processes are regulated across cell types and tissues. 
Therefore, it is important for the in depth understanding to develop novel interven-
tions to treat cancer, chronic inflammatory, and infectious diseases.
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